| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.CCM.0000194731.08896.99 |
| P698 | PubMed publication ID | 16424704 |
| P2093 | author name string | Josef Briegel | |
| Heinz-Otto Keinecke | |||
| Steven M Opal | |||
| Christian J Wiedermann | |||
| Helmut Ostermann | |||
| Joachim Kienast | |||
| Johannes N Hoffmann | |||
| Richard Strauss | |||
| Mathias Juers | |||
| Brian L Warren | |||
| KyberSept Investigators | |||
| P2860 | cites work | Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production | Q44248061 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| sepsis | Q183134 | ||
| P304 | page(s) | 285-292 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Critical Care Medicine | Q5186605 |
| P1476 | title | High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety | |
| P478 | volume | 34 |
| Q41927869 | A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. |
| Q90243063 | A human antithrombin isoform dampens inflammatory responses and protects from organ damage during bacterial infection |
| Q24816510 | A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis |
| Q33927961 | A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection. |
| Q33753012 | A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis |
| Q57463140 | Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
| Q64229720 | Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study |
| Q41694620 | Adjuvant treatment of sepsis: what is known? |
| Q46003363 | All of the King's soldiers. |
| Q35829030 | Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulation |
| Q47574722 | Antibodies against RAGE in sepsis and inflammation: implications for therapy |
| Q37784309 | Anticoagulant heparan sulfate to not clot--or not? |
| Q92981705 | Anticoagulant therapy for septic coagulopathy and disseminated intravascular coagulation: where do KyberSept and SCARLET leave us? |
| Q24186159 | Antithrombin III for critically ill patients |
| Q24242053 | Antithrombin III for critically ill patients |
| Q51076281 | Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study |
| Q36986076 | Antithrombin is protective against myocardial ischemia and reperfusion injury |
| Q89950751 | Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin |
| Q35629808 | Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease |
| Q37138741 | Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan |
| Q35201124 | Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. |
| Q37724049 | Blood coagulation disorders in septic patients |
| Q36423261 | Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis |
| Q43517013 | Coagulation deficiencies: a look to the future |
| Q33409905 | Contribution of protein Z and protein Z-dependent protease inhibitor in generalized Shwartzman reaction |
| Q39780897 | Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey |
| Q35107098 | Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation |
| Q53621386 | Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin. |
| Q48108424 | Evaluation of between-, within- and day-to-day variation of coagulation measured by rotational thrombelastometry (ROTEM). |
| Q47151375 | Fluid resuscitation targeting sepsis-induced cardiovascular dysfunction: severity of disease as effect modifier |
| Q33385962 | Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats. |
| Q38270791 | Heparin protects against septic mortality via apoE-antagonism |
| Q34643529 | Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. |
| Q40067011 | High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats |
| Q43202935 | High-dose antithrombin III prevents heat stroke by attenuating systemic inflammation in rats |
| Q37949639 | Immunomodulatory therapy for sepsis: an update |
| Q51332285 | Is Coagulopathy an Appropriate Therapeutic Target During Critical Illness Such as Trauma or Sepsis? |
| Q38207933 | Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). |
| Q37805910 | Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. |
| Q37287790 | Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin |
| Q41595614 | Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation |
| Q92174594 | Optimal Timing and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated Intravascular Coagulation |
| Q27013790 | PAMPs and DAMPs as triggers for DIC |
| Q84464759 | Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation |
| Q57159238 | Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation |
| Q42096335 | Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates |
| Q43182531 | Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q37562996 | Severe sepsis and septic shock: management and performance improvement. |
| Q29615429 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 |
| Q24644984 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 |
| Q58106436 | Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice |
| Q35107094 | The Japanese guidelines for the management of sepsis |
| Q59675885 | The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice |
| Q33950741 | The host response to sepsis and developmental impact |
| Q36934401 | The pathogenesis of sepsis. |
| Q34501341 | Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases |
| Q79822512 | [Development of intensive care medicine in Austria--with special reference to the internal medicine intensive care unit] |
| Q80051658 | [Endogenous anticoagulant therapy for sepsis. Success and failure] |
| Q86544066 | [International guidelines of the Surviving Sepsis Campaign : update 2012] |
| Q83286642 | [Severe sepsis and disseminated intravascular coagulation. Supplementation with antithrombin] |
Search more.